Ontorpacept

昂托瑞泊西普

Report date: 2023/05/05 17:40:47

Base Information

Drug NameOntorpacept
Drug Alias NameTTI-621
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaSolid tumoursSkin Neoplasms +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Health Network (Uhn)The Hospital For Sick ChildrenTrillium Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTrillium Therapeutics IncNational Cancer Institute
Inactive CompaniesPfizer Inc
Active IndicationsPrimary mediastinal B cell lymphomaSkin NeoplasmsMultiple Myeloma +[8] 
Inactive IndicationsSolid tumoursHematologic NeoplasmsBreast Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A